Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Ifeanyichukwu Ifechidere: Direct Oral Anticoagulants Broke Traditional Coag Testing
Ifeanyichukwu Ifechidere/LinkedIn
Mar 29, 2026, 16:01

Ifeanyichukwu Ifechidere: Direct Oral Anticoagulants Broke Traditional Coag Testing

Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:

”DOACs and the Lab Dilemma: When Anticoagulation Outpaced Our Tests

‘Direct oral anticoagulants broke traditional coag testing.’

That may sound dramatic—but in many ways, it’s true.

For decades, laboratories and clinicians relied on PT and APTT as the backbone of coagulation assessment. They were predictable, interpretable, and clinically actionable. Then came DOACs… and the rules changed.

The Problem: Familiar Tests, Unfamiliar Behavior

Direct oral anticoagulants (DOACs)—including factor Xa inhibitors and direct thrombin inhibitors—interact with coagulation assays in ways that are:

  • Variable (reagent-dependent)
  • Drug-specific
  • Often misleading

PT and APTT are no longer reliable indicators of anticoagulant effect

  • A normal PT/APTT does NOT exclude clinically relevant DOAC levels
  • A prolonged result does NOT quantify anticoagulation

In short: we’re using tools built for a different era.

The Shift: From Global Tests to Targeted Assays

To truly understand DOAC activity, we need drug-specific testing strategies:

  • Anti-Xa assays (calibrated for specific DOACs) are used for rivaroxaban, apixaban, edoxaban
  • Dilute thrombin time (dTT) or ecarin-based assays are used for dabigatran

These assays provide:

  • Quantitative insight
  • Drug-level estimation
  • Clinical relevance in bleeding, thrombosis, or urgent procedures

But access remains inconsistent—and interpretation isn’t always straightforward.

The Real Dilemma Isn’t the Lab… It’s the Gap

We’re facing a critical disconnect:

  • Clinicians may request PT/APTT expecting clarity
  • Labs know these tests may mislead in DOAC-treated patients
  • Results are reported… but not always understood

‘Are clinicians clear on DOAC lab interpretation?’

In many cases—not fully. And that’s not a criticism—it’s a system challenge.

Where Do We Go From Here?

  • Stronger lab–clinician communication
  • Clear interpretative comments on reports
  • Wider access to DOAC-calibrated assays
  • Ongoing education across disciplines

Because the question is no longer ‘What’s the PT?’
It’s ‘What does this result actually mean for this patient on a DOAC?’

Bottom Line
DOACs didn’t just change anticoagulation therapy—they exposed the limitations of our legacy testing systems.
As laboratory professionals, we’re not just reporting numbers anymore.
We’re guiding interpretation in a new and evolving landscape.”

Ifeanyichukwu Ifechidere: Direct Oral Anticoagulants Broke Traditional Coag Testing

More posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.

aPTT Direct Oral Anticoagulants DOACs Health Hematology Hemostasis Hemostasis News Hemostasis Today Ifeanyichukwu Ifechidere Medicine PT thrombosis Xa inhibitors
NewsFeed